Today we’re announcing $106M in new funding led by Altimeter Capital and Bezos Expeditions. This brings our total to $150M to scale our frontier AI models which make biology programmable. Our frontier models have generated functional proteins (Nature Biotech, 2023), created the first CRISPR system designed from scratch (Nature, 2025), and showed clear scaling behavior (NeurIPS spotlight, 2025). The opportunities ahead are unimaginable. If you’re excited by shaping the future of biology – join us in pushing the science forward. Forbes: forbes.com/sites/amyfeldman/… Press Release: businesswire.com/news/home/2… -- Nature Biotech, 2023: nature.com/articles/s41587-0… NeurIPS spotlight, 2025: biorxiv.org/content/10.1101/… Nature, 2025: nature.com/articles/s41586-0…

can AI scale it? at ASGCT this month, we showed AI can ~10x the addressable coverage when designing base editors (the molecules behind the Verve/Lilly announcement), among other benefits. that translates to an unlock for patients by dramatically expanding addressable targets for therapeutic gene editing we don't want a world where this is a one off breakthrough. we want a repeatable engine.

we live in the future - the next step is designing large gene insertions and fine scale editing with AI 👀 @ProfluentBio “One dose of VERVE-102 (in vivo base editor) led to dose-dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels.”

cool to see 3 nature papers published in one day on AI for science. contrary to AI replacement doomerism, i firmly see the future being defined by the scientist. incredible time to build previous decades focused builder energy on social media or enterprise SaaS. this is insanely more exciting and impactful. drug discovery clearly is one of the largest impact areas. i hope it will extend beyond that as well

At PEGS Boston? Don't miss our Lead Protein Design Scientist Jeliazko Jeliazkov presenting "Designing Optimal Proteins at Scale" Generating proteins that are simultaneously optimal across many properties (affinity, stability, developability, and beyond) is a hard problem. Jeli's sharing our work on alignment of our foundational AI models as a path to multi-parameter protein optimization, with applications from gene editors to antibodies. Interested in learning more about our multi-parameter optimization work? Shoot us a DM.

We're at @ASGCTherapy today sharing something we've been heads down building: using our AI models to scale base editing for personalized medicine. The gap between what's theoretically correctable and what we can actually fix today is huge. We think AI can close that gap. Not there? Peter Cameron, our SVP of Gene Editing, breaks it down here. Interested in learning more? Shoot us a DM.

What do AI-designed proteins look like in the field? 🌾🚜 On Monday, @thisismadani joins @Corteva at @WorldAgriTech to share how Profluent's AI models are engineering proteins for gene editing solutions that address real problems farmers face. March 16 · 12:30pm · San Francisco · World Agri-Tech worldagritechusa.com/agenda-…

Great event at @benchling! We're excited to be among so many great teams creating more and better medicines with AI. Thanks for having us, @sajithw

Our BD team just wrapped a fun year-end off-site (spoiler: we did an escape room!) Now we’re gearing up for the annual trek to JPM next month. If you’d like to connect and learn more about the intersection of AI and protein design—gene editing, antibodies, and beyond—reach out, our DMs are open.